Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis

Platelets

Volumn 22, Issue 7, 2011, Pages 537-546

  Madsen, Esben Hjorth ^a,b   Gehr, Norbert Rudolf ^b   Johannesen, Nils Lauge ^b   Schmidt, Erik Berg ^b   Kristensen, Søren Risom ^a  

^a VIBORG HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aspirin resistance; clopidogrel resistance; peripheral artery disease; platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANALYZER; ARTICLE; BLOOD CLOTTING PARAMETERS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IMPEDANCE AGGREGOMETRY; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET FUNCTION ANALYZER; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

AGED; ASPIRIN; ATHEROSCLEROSIS; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 80053638595     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.577254     Document Type: Article

References (41)

1. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329-1339.
3. Steinhubl SR, Berger PB, Mann III JT, Fry ET, DeLago A, Wilmer C, Topal EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288(19):2411- 2420.
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345(7):494-502.
5. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108(1):37-42.
6. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4(3):542-549.
7. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105(14):1650-1655.
8. Geisler T, Langer H, Wydymus M, Gohring K, Zurn C, Bigalke B, Stellos K, May AE. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27(20):2420-2425.
9. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107(23):2908-2913.
10. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the prepare poststenting study. J Am Coll Cardiol 2005;46(10):1820-1826.
11. Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, Akyuz U, Unal Dai S, Narin A. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol 2007;23(3):201-206.
12. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28(14):1702-1708.
13. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, Gensini GF, Abbate R, Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5(9):1839-1847.
14. Poulsen TS, Kristensen SR, Korsholm L, Haghfelt T, Jorgensen B, Licht PB, Mickley H. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res 2007;120(4):477-484.
15. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29(8):992-1000.
16. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schö;mig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008;99(1):121-126.
17. Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerico A, Biagini A. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. Thromb Res 2006;118(4):487-493.
18. Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schö;mig A, Kastrati A, von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010;103(1):151-159.
19. Mueller T, Haltmayer M, Poelz W, Haidinger D. Monitoring aspirin 100mg and clopidogrel 75mg therapy with the PFA- 100 device in patients with peripheral arterial disease. Vasc Endovascular Surg 2003;37(2):117-123.
20. Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: Therapeutic implications. Ann Vasc Surg 2002;16(2):246-258.
21. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4(12):2547-2552.
22. Reny JL, de MP, Dauzat M, Fontana P. Use of the PFA-100 TM closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2008;6(3):444-450.
23. Madsen EH, Schmidt EB, Gehr N, Johannesen NL, Kristensen SR. Testing aspirin resistance using the platelet function analyzer-100: Some methodological caveats and considerations. J Thromb Haemost 2008;6(2):386-388.
24. Madsen EH, Schmidt EB, Maurer-Spurej E, Kristensen SD. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008; 19(5):335-341.
25. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929.
26. Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009;20(1):7-11.
27. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;46(9):1705-1709.
28. von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays: PFA-100 and multiple electrode aggregometry. In: 36th hemophilia symposium, Hamburg 2005, Springer, Berlin Heidelberg; 2007. pp. 243-251.
29. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49(6):657-666.
30. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo D, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56(12):919-933.
31. von BN, Taubert D, Pogatsa-Murray G, Schö;mig E, Kastrati A, Schö;mig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-choice (Intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005;112(19):2946- 2950.
32. Gasse C, Jacobsen J, Larsen AC, Schmidt EB, Johannesen NL, Videbaek J, Sorensen HT, Johnsen SP. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction. Eur J Vasc Endovasc Surg 2008; 35(1):51-58.
33. Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008;19(2):119-124.
34. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010;103(6): 1245-1253.
35. Pedersen SB, Grove EL, Nielsen HL, Mortensen J, Kristensen SD, Hvas AM. Evaluation of aspirin response by multiplate whole blood aggregometry and light transmission aggregometry. Platelets 2009;20(6):415-420.
36. Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, Bjornsen S, Schjelderup NM, Ameln W, Ng EC, et al. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest 2008; 68(3):185-191.
37. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, Defranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95(8):973-975.
38. Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B. Using the platelet function analyzer-100 for monitoring aspirin therapy. Thromb Res 2007;120(2): 161-172.
39. Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, verifynow, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem. 2010;56(5):839-847.
40. Paniccia R, Antonucci E, Maggini N, Miranda M, Gori AM, Marcucci R, Giusti B, Balzi D, Prisco D, Abbate R. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost 2010;104(2): 287-292.
41. Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schö;mig A, Kastrati A, Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105(1):107-112.